Repare Therapeutics Inc. (RPTX)

10.65 +0.46 (+4.51%) At close: 04:00PM EDT

Repare Therapeutics Inc.

7210 Frederick-Banting
Suite 100
Montreal, QC H4S 2A1
Canada

https://www.reparerx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 180

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Lloyd Mitchell Segal	Pres, CEO & Director	913.37k	148.07k	1964
Mr. Steve Forte	Exec. VP & CFO	608.52k	N/A	1979
Dr. Michael Zinda Ph.D.	Exec. VP & Chief Scientific Officer	655.28k	1.07M	1971
Dr. Maria Koehler M.D., Ph.D.	Exec. VP & Chief Medical Officer	669.83k	892.97k	1958
Dr. Daniel Durocher Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. Frank Sicheri Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. Agnel Sfeir Ph.D.	Co-Founder	N/A	N/A	N/A
Mr. Cameron Black	Exec. VP of Discovery	N/A	N/A	N/A
Dr. Kim A. Seth Ph.D.	Exec. VP & Chief Bus. Officer	N/A	N/A	N/A
Mr. Philip Herman	Exec. VP, Chief Commercial & Portfolio Devel. Officer	N/A	N/A	1980

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Corporate governance

Repare Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.